FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136936> ?p ?o ?g. }

• W4324136936 endingPage "TPS271" @default.
• W4324136936 startingPage "TPS271" @default.
• W4324136936 abstract "TPS271 Background: Combination immune checkpoint inhibitors (ICI) with ipilimumab and nivolumab has been shown to induce adaptive immune responses in patients with mCRPC, albeit resulting in modest clinical benefit. There is growing evidence that radiation may enhance the activity of ICI by modulating the tumour immune microenvironment. We hypothesize that the radionuclide 177 Lu-PSMA-617 may result in immunogenic cell death and therefore synergise with combination ICI to improve long term clinical outcomes. EVOLUTION aims to determine the activity and safety of ipilimumab and nivolumab in combination with 177 Lu-PSMA-617 in patients with mCRPC. Methods: This open label, multicentre, phase 2 study will randomly assign 100 participants with mCRPC in a 2:1 ratio stratified by site and prior exposure to docetaxel to either: the experimental combination of 177 Lu-PSMA-617 7.5 GBq every 6 weeks for up to 6 doses plus ipilimumab 3 mg/kg every 6 weeks x 4 doses and nivolumab 1 mg/kg every 3 weeks x 8 doses during induction, followed by nivolumab 480 mg every 4 weeks x 18 doses during maintenance or 177 Lu-PSMA-617 alone. Key eligibility criteria include progression on prior androgen receptor pathway inhibitors, no more than one line of prior chemotherapy, significant PSMA avidity on 68 GaPSMA-11 PET/CT (SUVmax ≥15 at one disease site and SUVmax ≥10 at measurable sites of disease > 10 mm), no FDG positive/PSMA negative disease and no contraindications to ICI. The primary endpoint is 12-month PSA progression-free survival (PSA-PFS). Secondary endpoints are PSA response rate, adverse events, radiographic-PFS, overall survival, objective response rate, duration of response and health-related quality of life. Correlative studies will evaluate exploratory biomarkers as potential predictive/prognostic factors. Assessments include clinical reviews and blood tests at baseline, then every 3-4 weeks; CT and bone scan at baseline, then every 12 weeks; 68 Ga-PSMA-11 and 18 F FDG PET/CTs at baseline; 68 Ga-PSMA-11 PET/CT at week 24 and 177 Lu-PSMA-617 SPECT/CT 24 hours after each 177 Lu-PSMA-617 dose. Translational bloods include circulating tumour DNA and peripheral blood mononuclear cells collected at baseline, weeks 13 and 25, and at radiological progression. Optional fresh biopsies will be collected at baseline, weeks 3-5 and at progression. A sample size of 100 provides 90% power at the 10% level of significance to reject the null hypothesis (that 1 year PSA-PFS is 20%) if the alternative hypothesis is true (that 1 year PSA-PFS is 35%). Accrual as of the 11 th of October 2022 is 23. Clinical trial information: NCT05150236 ." @default.
• W4324136936 created "2023-03-15" @default.
• W4324136936 creator A5006815287 @default.
• W4324136936 creator A5018783860 @default.
• W4324136936 creator A5018801649 @default.
• W4324136936 creator A5020632499 @default.
• W4324136936 creator A5020900919 @default.
• W4324136936 creator A5021111124 @default.
• W4324136936 creator A5024778370 @default.
• W4324136936 creator A5041831251 @default.
• W4324136936 creator A5044715236 @default.
• W4324136936 creator A5057708677 @default.
• W4324136936 creator A5061757629 @default.
• W4324136936 creator A5063276705 @default.
• W4324136936 creator A5064026461 @default.
• W4324136936 creator A5064732405 @default.
• W4324136936 creator A5066274807 @default.
• W4324136936 creator A5071471573 @default.
• W4324136936 creator A5078319177 @default.
• W4324136936 creator A5082406815 @default.
• W4324136936 creator A5085055388 @default.
• W4324136936 creator A5085333470 @default.
• W4324136936 date "2023-02-20" @default.
• W4324136936 modified "2023-10-12" @default.
• W4324136936 title "Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)." @default.
• W4324136936 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.tps271" @default.
• W4324136936 hasPublicationYear "2023" @default.
• W4324136936 type Work @default.
• W4324136936 citedByCount "3" @default.
• W4324136936 countsByYear W43241369362023 @default.
• W4324136936 crossrefType "journal-article" @default.
• W4324136936 hasAuthorship W4324136936A5006815287 @default.
• W4324136936 hasAuthorship W4324136936A5018783860 @default.
• W4324136936 hasAuthorship W4324136936A5018801649 @default.
• W4324136936 hasAuthorship W4324136936A5020632499 @default.
• W4324136936 hasAuthorship W4324136936A5020900919 @default.
• W4324136936 hasAuthorship W4324136936A5021111124 @default.
• W4324136936 hasAuthorship W4324136936A5024778370 @default.
• W4324136936 hasAuthorship W4324136936A5041831251 @default.
• W4324136936 hasAuthorship W4324136936A5044715236 @default.
• W4324136936 hasAuthorship W4324136936A5057708677 @default.
• W4324136936 hasAuthorship W4324136936A5061757629 @default.
• W4324136936 hasAuthorship W4324136936A5063276705 @default.
• W4324136936 hasAuthorship W4324136936A5064026461 @default.
• W4324136936 hasAuthorship W4324136936A5064732405 @default.
• W4324136936 hasAuthorship W4324136936A5066274807 @default.
• W4324136936 hasAuthorship W4324136936A5071471573 @default.
• W4324136936 hasAuthorship W4324136936A5078319177 @default.
• W4324136936 hasAuthorship W4324136936A5082406815 @default.
• W4324136936 hasAuthorship W4324136936A5085055388 @default.
• W4324136936 hasAuthorship W4324136936A5085333470 @default.
• W4324136936 hasConcept C121608353 @default.
• W4324136936 hasConcept C126322002 @default.
• W4324136936 hasConcept C143998085 @default.
• W4324136936 hasConcept C203092338 @default.
• W4324136936 hasConcept C2776694085 @default.
• W4324136936 hasConcept C2776999253 @default.
• W4324136936 hasConcept C2777701055 @default.
• W4324136936 hasConcept C2780030458 @default.
• W4324136936 hasConcept C2781190966 @default.
• W4324136936 hasConcept C2781433595 @default.
• W4324136936 hasConcept C2989005 @default.
• W4324136936 hasConcept C2993559085 @default.
• W4324136936 hasConcept C31760486 @default.
• W4324136936 hasConcept C535046627 @default.
• W4324136936 hasConcept C71924100 @default.
• W4324136936 hasConceptScore W4324136936C121608353 @default.
• W4324136936 hasConceptScore W4324136936C126322002 @default.
• W4324136936 hasConceptScore W4324136936C143998085 @default.
• W4324136936 hasConceptScore W4324136936C203092338 @default.
• W4324136936 hasConceptScore W4324136936C2776694085 @default.
• W4324136936 hasConceptScore W4324136936C2776999253 @default.
• W4324136936 hasConceptScore W4324136936C2777701055 @default.
• W4324136936 hasConceptScore W4324136936C2780030458 @default.
• W4324136936 hasConceptScore W4324136936C2781190966 @default.
• W4324136936 hasConceptScore W4324136936C2781433595 @default.
• W4324136936 hasConceptScore W4324136936C2989005 @default.
• W4324136936 hasConceptScore W4324136936C2993559085 @default.
• W4324136936 hasConceptScore W4324136936C31760486 @default.
• W4324136936 hasConceptScore W4324136936C535046627 @default.
• W4324136936 hasConceptScore W4324136936C71924100 @default.
• W4324136936 hasFunder F4320320501 @default.
• W4324136936 hasIssue "6_suppl" @default.
• W4324136936 hasLocation W43241369361 @default.
• W4324136936 hasOpenAccess W4324136936 @default.
• W4324136936 hasPrimaryLocation W43241369361 @default.
• W4324136936 hasRelatedWork W2588686192 @default.
• W4324136936 hasRelatedWork W2800160190 @default.
• W4324136936 hasRelatedWork W2899127460 @default.
• W4324136936 hasRelatedWork W2973740076 @default.
• W4324136936 hasRelatedWork W2976744492 @default.
• W4324136936 hasRelatedWork W3043703771 @default.
• W4324136936 hasRelatedWork W4236421112 @default.
• W4324136936 hasRelatedWork W4241093956 @default.
• W4324136936 hasRelatedWork W4313890856 @default.
• W4324136936 hasRelatedWork W3108601240 @default.
• W4324136936 hasVolume "41" @default.
• W4324136936 isParatext "false" @default.

• next